ZA200708187B - Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-D]pyrimidine derivatives - Google Patents

Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-D]pyrimidine derivatives

Info

Publication number
ZA200708187B
ZA200708187B ZA200708187A ZA200708187A ZA200708187B ZA 200708187 B ZA200708187 B ZA 200708187B ZA 200708187 A ZA200708187 A ZA 200708187A ZA 200708187 A ZA200708187 A ZA 200708187A ZA 200708187 B ZA200708187 B ZA 200708187B
Authority
ZA
South Africa
Prior art keywords
thiazolo
amino
substituted
novel
pyrimidine derivatives
Prior art date
Application number
ZA200708187A
Other languages
English (en)
Inventor
Nordvall Gunnar
Rein Tobias
Ray Colin
Sohn Daniel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200708187B publication Critical patent/ZA200708187B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200708187A 2005-04-06 2007-09-25 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-D]pyrimidine derivatives ZA200708187B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06

Publications (1)

Publication Number Publication Date
ZA200708187B true ZA200708187B (en) 2008-11-26

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708187A ZA200708187B (en) 2005-04-06 2007-09-25 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-D]pyrimidine derivatives

Country Status (31)

Country Link
US (2) US7947693B2 (fr)
EP (1) EP1869056B1 (fr)
JP (1) JP5165553B2 (fr)
KR (1) KR101335055B1 (fr)
CN (1) CN101193897B (fr)
AR (1) AR055890A1 (fr)
AT (1) ATE487727T1 (fr)
AU (1) AU2006231836B2 (fr)
BR (1) BRPI0609738A2 (fr)
CA (1) CA2604017C (fr)
CY (1) CY1111316T1 (fr)
DE (1) DE602006018124D1 (fr)
DK (1) DK1869056T3 (fr)
ES (1) ES2354450T3 (fr)
HK (1) HK1118556A1 (fr)
HR (1) HRP20110047T1 (fr)
IL (1) IL185912A0 (fr)
MX (1) MX2007012060A (fr)
NO (1) NO20075603L (fr)
NZ (1) NZ561460A (fr)
PL (1) PL1869056T3 (fr)
PT (1) PT1869056E (fr)
RS (1) RS51581B (fr)
RU (1) RU2419623C2 (fr)
SA (1) SA06270072B1 (fr)
SI (1) SI1869056T1 (fr)
TW (1) TW200714605A (fr)
UA (1) UA90707C2 (fr)
UY (1) UY29454A1 (fr)
WO (1) WO2006107258A1 (fr)
ZA (1) ZA200708187B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806145B1 (fr) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Médicament contre les maladies inflammatoires
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
WO2008039139A1 (fr) 2006-09-29 2008-04-03 Astrazeneca Ab Nouveaux dérivés de [1, 3 ]thiazolo[4, 5-d]pyrimidine-2(3h)-amine 5,7-disubstitutés et leur utilisation en thérapie
HUE027098T2 (en) 2008-03-07 2016-08-29 Acraf 1-Benzyl-3-hydroxymethylindazole derivatives and their use in the treatment of MCP-1, CX3CR1 expression-based diseases
KR101581829B1 (ko) 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도
SG188178A1 (en) 2008-03-07 2013-03-28 Acraf 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (fr) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Méthodes d'inhibition de la métastase d'un cancer
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
ES2642805T3 (es) 2013-03-12 2017-11-20 Eisai R&D Management Co., Ltd. Sal de un derivado del ácido pirrolidín-3-ilacético y cristales de esta
EP3049086A4 (fr) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisation
WO2016200939A1 (fr) * 2015-06-08 2016-12-15 The Johns Hopkins University 7-amino-5-thio-thiazolo[4,5-d]pyrimidines radiofluorées à utiliser pour imager un récepteur de la fractalkine (cx3cr1)
WO2018204370A1 (fr) 2017-05-02 2018-11-08 Drexel University Antagonistes de cx3cr1 à petites molécules, et procédés les utilisant
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
WO2024083933A1 (fr) 2022-10-19 2024-04-25 Astrazeneca Ab 1,3,5-triazines 2,4,6-trisubstituées en tant que modulateurs de cx3cr1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (fr) * 1955-01-03
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
CA2031803C (fr) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Derives de glycopeptides
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
WO1999051608A1 (fr) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company PYRIMIDINES ET PYRIDINES THIAZOLO[4,5-d] UTILISEES COMME ANTAGONISTES DU FACTEUR LIBERATEUR DE CORTICOTROPHINE (CRF)
DE69936052T2 (de) 1998-05-01 2008-01-17 Eli Lilly And Co., Indianapolis N1 modifizierte glycopeptide
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
AU2001232556A1 (en) 2000-02-11 2001-08-20 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DK2526996T3 (da) * 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulering til intrakutan injektion
EP1675862A1 (fr) * 2003-10-07 2006-07-05 AstraZeneca AB Nouvelles 4-amino-thiazolo 4,5-d| pyrimidines substituees en 2, utiles comme antagonistes du recepteur chimiokine, notamment cx3cr1
EP1844054A2 (fr) * 2004-12-17 2007-10-17 AstraZeneca AB Derives de thiazolopyrimidine pour la modulation de l'activite du recepteur chemokine
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
RU2419623C2 (ru) 2011-05-27
UY29454A1 (es) 2006-11-30
RS51581B (en) 2011-08-31
KR20080004483A (ko) 2008-01-09
US7947693B2 (en) 2011-05-24
CN101193897A (zh) 2008-06-04
KR101335055B1 (ko) 2013-12-02
DK1869056T3 (da) 2011-02-07
PT1869056E (pt) 2011-01-13
CY1111316T1 (el) 2015-08-05
TW200714605A (en) 2007-04-16
AR055890A1 (es) 2007-09-12
AU2006231836A1 (en) 2006-10-12
MX2007012060A (es) 2007-12-13
UA90707C2 (en) 2010-05-25
CN101193897B (zh) 2010-12-01
US20080214578A1 (en) 2008-09-04
SA06270072B1 (ar) 2009-02-07
IL185912A0 (en) 2008-01-06
NZ561460A (en) 2010-12-24
US20110092519A1 (en) 2011-04-21
EP1869056B1 (fr) 2010-11-10
CA2604017C (fr) 2012-03-06
RU2007140551A (ru) 2009-05-20
WO2006107258A1 (fr) 2006-10-12
DE602006018124D1 (de) 2010-12-23
JP2008535835A (ja) 2008-09-04
JP5165553B2 (ja) 2013-03-21
ATE487727T1 (de) 2010-11-15
BRPI0609738A2 (pt) 2011-10-18
ES2354450T3 (es) 2011-03-15
SI1869056T1 (sl) 2011-02-28
PL1869056T3 (pl) 2011-04-29
EP1869056A1 (fr) 2007-12-26
NO20075603L (no) 2008-01-04
HK1118556A1 (en) 2009-02-13
US9440992B2 (en) 2016-09-13
EP1869056A4 (fr) 2010-02-17
HRP20110047T1 (hr) 2011-03-31
CA2604017A1 (fr) 2006-10-12
AU2006231836B2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
IL185912A0 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
ZA200805294B (en) Pyrimidine derivatives
GB0525080D0 (en) Pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
IL181386A0 (en) Pyrimidine derivatives
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
IL192236A0 (en) Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
EP1724267A4 (fr) Derive de pyrimidine
IL179914A0 (en) Pyrimidine derivatives
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
GB0415364D0 (en) Pyrimidine derivatives
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
GB0525081D0 (en) Pyrimidine derivatives
IL185913A0 (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives
HK1126204A1 (en) Substituted bicyclic pyrimidone derivatives
HRP20130533T1 (en) Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide
IL196107A0 (en) PRODRUGS OF-5-AMINO-3-(3'-DEOXY-??-D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
PL1644343T3 (pl) Pochodne 5-podstawionego chinazolinonu
IL191568A0 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
IL190989A0 (en) Thiazolo [4,5-c]pyridine derivatives
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
TWI372760B (en) A pyrazolo[1,5-a]pyrimidine compound
ZA200600471B (en) 7-substituted 3-nitro-pyrazolo[1,5-A] pyrimidines